Please select the eligibility criteria that correspond to the clinical trial below.
Title: Methocarbamol and Orphenadrine for Acute, Non-traumatic, Non-radicular Low Back Pain: A Randomized, Placebo Controlled, 3-armed Study
Brief Summary: Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone


Options:
A: Inclusion Criteria:

* Lower back pain
* Male or female in generally good health, from 18 to 55 years of age (inclusive)

Exclusion Criteria:

* Pregnant or lactating
* Subject has evidence or history of radiculopathy, i.e. sciatica extending below the knee (numbness, tingling, or shooting pain), or other neurologic deficits (abnormal straight leg raise test, patellar reflexes, and/or bowel and bladder function);
* Subject has a history of previous back surgery;
* Subject has back pain resulting from traumatic injury involving physical evidence of bruising, swelling, or inflammation to the abdomen or low back area which occurred less than 48 hours prior to enrollment
* Has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study
* Is a member or relative of the study site staff, CRO or Sponsor organization directly involved with the study or had a household member or relative participate concurrently or previously in this study
* Has previously been enrolled in this study
B: Inclusion Criteria:

* Acute LBP(with or without leg pain), with onset within past 4 weeks
* Severe disability as assessed by an Oswestry Disability Index of 60% or higher
* Age between 20 and 60
* Given consent to lumbar MRI
* Voluntary participation with written consent given to study consent form

Exclusion Criteria:

* Diagnosis of serious disease(s) which are possible causes of back pain such as malignancy, vertebral fracture, spinal infection, inflammatory spondylitis, cauda equina compression, etc.
* Prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, Alzheimer's disease, epilepsy, etc.
* Progressive neurologic deficit(s) or concurrent severe neurological symptoms
* Unsuitable for or at risk of complications from acupuncture treatment such as patients with clotting disorders, severe diabetes with risk of infection, serious cardiovascular disease, or undergoing anticoagulant treatment, etc.
* Under prescription of corticosteroids, immuno-suppressant drugs, psychiatric medicine, or other medication considered unsuitable for subjects by the researcher
* Experience of gastroenteric complications after taking NSAIDs or currently undergoing treatment for digestive disorders
* During pregnancy or suspected pregnancy
* Subjects considered unsuitable for clinical trial by the researcher
C: Inclusion Criteria:

* LBP duration \<= 2 weeks
* No trauma to low back within previous month
* No radicular symptoms
* No history of low back pain or history of only infrequent episodes

Exclusion Criteria:

* Medication allergies or contra-indications
* Not available for follow-up
* Chronic pain syndrome
D: Inclusion criteria:

* Signed and dated written informed consent at Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation.
* Male or female patients who are \>=18 years with current diagnosis of acute back pain or of neck pain for at least 24 hours, but less than 21 days.
* Acute back pain or acute neck pain resulting in Pain on Movement (POM) \>=5 on the 0-10 Numerical Rating Scale (NRS) for at least one POM procedure out of 5 standardised procedures.
* Sensitivity to algometric pressure on the painful trigger point \<= 25 N/cm².
* Women of childbearing potential must be ready and able to use highly effective methods of birth control.
* Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaires.
* Examined by the attending physician and medically cleared to participate in the study
* In good general health, with a body mass index (BMI) \< 30, and have no contraindications to any of the study medication

Exclusion criteria:

* History of 3 or more episodes of back or neck pain in the last 6 months excluding the current episode.
* Patients with pain at rest \>= 9
* Patient with chronic back or neck pain as defined as pain for 3 weeks or longer.
* Back or neck pain that is attributable to any identifiable cause (eg. disc prolapse, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological diseases or tumour)
* Any strains of the back or neck muscles documented by clinical evaluation and anamnesis that occurred 21 days to 3 months prior to the screening visit.
* Surgery due to back or neck pain or rehabilitation due to back or neck pain in the last 12 months.
* Prior use within the last 3 days before Visit 1 or concomitant use of any anti- inflammatory drugs, heparinoids, muscle relaxants or analgesics (including but not limited to short-acting glucocorticoids, non-steroidal anti-inflammatory drugs \[NSAIDs\], herbal preparations) for the same indication or other indications.
* Spinal injections should have been discontinued in due time (investigator's judgment) before patient enrollment to allow complete wash-out of the active ingredient based on investigator's judgment.
* Known severe hepatocellular insufficiency, severe renal insufficiency or Gilbert's syndrome (Morbus Meulengracht)
* Patients taking Central Nervous System (CNS) or other psychotropic drugs, or any nutritional supplement known to have psychotropic effects such as St. John's Wort, Chapparal, Comfrey, Germander, Gin Bu Huan, Kava, Pennyroyal Skullcap, or Valerian within two months of taking the first dose of study medication. Patients who have been on stable doses of these medications for at least two months will be allowed into the study, as long as they maintain this dose throughout the study, and their condition is judged stable by the Principal Investigator
* Any other medical condition that would interfere with efficacy and safety assessments based on investigator's judgment or any on-going clinical condition that would jeopardize patient's or site personnel's safety or study compliance based on investigator judgment
* Further exclusion criteria apply

Answer: C